212 related articles for article (PubMed ID: 15882278)
1. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes.
Boven K; Stryker S; Knight J; Thomas A; van Regenmortel M; Kemeny DM; Power D; Rossert J; Casadevall N
Kidney Int; 2005 Jun; 67(6):2346-53. PubMed ID: 15882278
[TBL] [Abstract][Full Text] [Related]
2. Pure red-cell aplasia "epidemic"--mystery completely revealed?
Locatelli F; Del Vecchio L; Pozzoni P
Perit Dial Int; 2007 Jun; 27 Suppl 2():S303-7. PubMed ID: 17556324
[TBL] [Abstract][Full Text] [Related]
3. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery.
Boven K; Knight J; Bader F; Rossert J; Eckardt KU; Casadevall N
Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii33-40. PubMed ID: 15824129
[TBL] [Abstract][Full Text] [Related]
4. Epoetin-associated pure red cell aplasia: past, present, and future considerations.
McKoy JM; Stonecash RE; Cournoyer D; Rossert J; Nissenson AR; Raisch DW; Casadevall N; Bennett CL
Transfusion; 2008 Aug; 48(8):1754-62. PubMed ID: 18482185
[TBL] [Abstract][Full Text] [Related]
5. Recognition and identification of UV-absorbing leachables in EPREX pre-filled syringes: an unexpected occurrence at a formulation-component interface.
Pang J; Blanc T; Brown J; Labrenz S; Villalobos A; Depaolis A; Gunturi S; Grossman S; Lisi P; Heavner GA
PDA J Pharm Sci Technol; 2007; 61(6):423-32. PubMed ID: 18410043
[TBL] [Abstract][Full Text] [Related]
6. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk.
Cournoyer D; Toffelmire EB; Wells GA; Barber DL; Barrett BJ; Delage R; Forrest DL; Gagnon RF; Harvey EA; Laneuville P; Patterson BJ; Poon MC; Posen GA; Messner HA;
J Am Soc Nephrol; 2004 Oct; 15(10):2728-34. PubMed ID: 15466278
[TBL] [Abstract][Full Text] [Related]
7. Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS).
Macdougall IC; Casadevall N; Locatelli F; Combe C; London GM; Di Paolo S; Kribben A; Fliser D; Messner H; McNeil J; Stevens P; Santoro A; De Francisco AL; Percheson P; Potamianou A; Foucher A; Fife D; Mérit V; Vercammen E;
Nephrol Dial Transplant; 2015 Mar; 30(3):451-60. PubMed ID: 25239637
[TBL] [Abstract][Full Text] [Related]
8. Pure red-cell aplasia and epoetin therapy.
Bennett CL; Luminari S; Nissenson AR; Tallman MS; Klinge SA; McWilliams N; McKoy JM; Kim B; Lyons EA; Trifilio SM; Raisch DW; Evens AM; Kuzel TM; Schumock GT; Belknap SM; Locatelli F; Rossert J; Casadevall N
N Engl J Med; 2004 Sep; 351(14):1403-8. PubMed ID: 15459301
[TBL] [Abstract][Full Text] [Related]
9. Interaction of polysorbate 80 with erythropoietin: a case study in protein-surfactant interactions.
Villalobos AP; Gunturi SR; Heavner GA
Pharm Res; 2005 Jul; 22(7):1186-94. PubMed ID: 16028020
[TBL] [Abstract][Full Text] [Related]
10. [Pure red cell aplasia in erythropoietin therapy in patients with kidney failure].
Opatrný K
Cas Lek Cesk; 2003; 142(12):741-5. PubMed ID: 14746223
[TBL] [Abstract][Full Text] [Related]
11. Investigating Serious Adverse Drug Reactions in Patients Receiving Erythropoiesis-Stimulating Agents: A Root Cause Analysis Using the "ANTICIPATE" Framework.
Jacob S; Nichols J; Macdougall IC; Qureshi Z; Chen B; Yang YT; Norris LB; Bennett CL
Am J Ther; 2018; 25(6):e670-e674. PubMed ID: 30169374
[TBL] [Abstract][Full Text] [Related]
12. Epoetins: differences and their relevance to immunogenicity.
Haselbeck A
Curr Med Res Opin; 2003; 19(5):430-2. PubMed ID: 13678480
[TBL] [Abstract][Full Text] [Related]
13. Importance of biologic follow-ons: experience with EPO.
Casadevall N; Rossert J
Best Pract Res Clin Haematol; 2005; 18(3):381-7. PubMed ID: 15792912
[TBL] [Abstract][Full Text] [Related]
14. Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another.
Macdougall IC
Curr Med Res Opin; 2004 Jan; 20(1):83-6. PubMed ID: 14741076
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin-Associated PRCA: Still an Unsolved Mystery.
Schellekens H; Jiskoot W
J Immunotoxicol; 2006 Sep; 3(3):123-30. PubMed ID: 18958692
[TBL] [Abstract][Full Text] [Related]
16. An in vivo model to assess factors that may stimulate the generation of an immune reaction to erythropoietin.
Ryan MH; Heavner GA; Brigham-Burke M; McMahon F; Shanahan MF; Gunturi SR; Sharma B; Farrell FX
Int Immunopharmacol; 2006 Apr; 6(4):647-55. PubMed ID: 16504928
[TBL] [Abstract][Full Text] [Related]
17. Acquired red cell aplasia in association with the use of recombinant erythropoietin in chronic renal failure.
Lim LC
Hematology; 2005 Jun; 10(3):255-9. PubMed ID: 16019474
[TBL] [Abstract][Full Text] [Related]
18. Eprex (recombinant human erythropoietin alfa) and pure red cell aplasia--recommendations for administration to patients with CRF.
S Afr Med J; 2003 Nov; 93(11):839. PubMed ID: 14677505
[No Abstract] [Full Text] [Related]
19. Evaluation of the immuno-stimulatory potential of stopper extractables and leachables by using dendritic cells as readout.
Mueller R; Karle A; Vogt A; Kropshofer H; Ross A; Maeder K; Mahler HC
J Pharm Sci; 2009 Oct; 98(10):3548-61. PubMed ID: 19226629
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing the immunogenicity of therapeutic proteins.
Schellekens H
Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi3-9. PubMed ID: 15958824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
